Glycosylation News and Research

RSS

Genetic interactions may shed light on NGLY1 deficiency

In 2012, four-year-old Bertrand Might became the first-ever patient diagnosed with a rare genetic disorder called N-glycanase (NGLY1) deficiency. The discovery of this condition and Bertrand's diagnosis allowed doctors to look for other children with the same genetic defect. Since then, more than 60 additional patients have been found.

26 Jan 2021

Circulating antiphospholipid antibodies drive endothelial cell activation in COVID-19

With the emergence of COVID-19 (coronavirus disease 2019), researchers have been closely investigating the complex interplay between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the human immune system, and COVID-19 disease severity.

25 Jan 2021

Researchers use SARS-CoV-2 to bioengineer universal vaccine platform

Using SARS-CoV-2, a team of scientists from the United States has recently developed a bioengineered bacteriophage T4 nanoparticle structure using CRISPR technology that can be used as a universal platform to produce vaccines.

21 Jan 2021

Researchers develop new method for charting SARS-CoV-2 spike protein glycosylation

Researchers develop a novel, simple and affordable method for N-glycan fingerprinting based on enzymatic fluorescent glycan labeling and electrophoresis. This new method may help us understand important changes in glycosylation in the SARS-CoV-2 spike protein – something which could inform future therapeutic research.

20 Jan 2021

SARS-CoV-2 anti-N rigid monoclonal antibodies provide accurate early diagnosis

An interesting new preprint research paper that was posted on the bioRxiv* server recently describes the use of rigid monoclonal antibodies (mAbs) in contrast to flexible mAbs, and how this affects the binding of multiple mAbs to the same antigen.

17 Jan 2021

A high-temperature tolerant SARS-CoV-2 derived immunogen as a potential vaccine candidate

There have been significant efforts worldwide to combat COVID-19, the disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). One prominent strategy has been to develop vaccines against the virus. Numerous vaccine candidates are under development, and a handful have now been approved for use by several countries.

17 Jan 2021

Antibody-Fc-mediated innate immunity shapes COVID-19 severity

A short paper that appeared recently on the preprint bioRxiv server pointed to a link between specific characteristics of anti-SARS-CoV-2 antibodies associated with the severity of COVID-19.

12 Jan 2021

Researchers discover new metabolic vulnerability in a highly aggressive form of lung cancer

Researchers at the Children's Medical Center Research Institute at UT Southwestern (CRI) have discovered a new metabolic vulnerability in a highly aggressive form of non-small cell lung cancer (NSCLC).

5 Jan 2021

SARS-CoV-2 infection increases risk of severe COVID-19 in pregnant women, newborns

Recent analyses indicate that pregnant women and newborns may face elevated risks of developing more severe cases of COVID-19 following SARS-CoV-2 infection.

24 Dec 2020

Long-range allosteric influences on SARS-COV-2-ACE2 stability and detachment

The COVID-19 pandemic is caused by SARS-CoV-2, a novel beta-coronavirus which has numerous spike proteins on its membrane.

3 Dec 2020

N-Glycosylation sites may contribute to spike-mediated invasion by SARS-CoV-2

The sugar residues decorating the spike (S) protein of SARS-CoV-2 are essential to the viral-receptor binding.

3 Dec 2020

Ipom-F inhibits SARS-CoV-2 infection in vitro

An international team of researchers showed the small molecule inhibitor, ipomoeassin F (Ipom-F), blocks the translocation/insertion of the three protein targets for SARS-CoV-2 infection.

27 Nov 2020

Modified SARS-CoV-2 receptor-binding domain could increase vaccine efficacy, says study

A team of researchers from the USA and China have engineered a receptor-binding domain (RBD) that they claim improves the immunogenicity of multivalent SARS-CoV-2 vaccines. Their study, which was released on the bioRxiv* in November 2020, may help advance even more efficacious SARS-CoV-2 vaccine candidates in the future.

23 Nov 2020

New understanding of glycan signatures of the SARS-COV-2 S1 spike protein

A team of scientists from the University of Oxford, UK, has revealed that site-specific glycosylation differs between spike proteins derived from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and a viral vector-based vaccine candidate.

18 Nov 2020

Severe COVID-19 complications linked to gut barrier breakdown

A new study claims that severe COVID-19 is caused by a positive feedback loop triggered by systemic inflammation and mediated by abnormal gut permeability. This finding could potentially help open up new avenues of treatment.

18 Nov 2020

Promising yeast-expressed SARS-CoV-2 vaccine candidate effective in mice

Researchers at the Texas Children's Hospital Center for Vaccine Development, USA, have published a report on the preprint server bioRxiv that describes a yeast-expressed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor-binding domain (RBD) protein, a key target of current vaccine development efforts.

9 Nov 2020

Research sheds light on how encapsulated viruses hijack protein production systems

Researchers from the Universities of Melbourne, York, Warwick and Oxford have shed light on how encapsulated viruses like hepatitis B, dengue and SARS-CoV-2 hijack the protein manufacturing and distribution pathways in the cell - they have also identified a potential broad spectrum anti-viral drug target to stop them in their tracks.

6 Nov 2020

Furin cleavage site and D614G on SARS-CoV-2 spike evolved to balance infectivity, stability, cytopathicity

SARS-CoV-2 is the causative agent of COVID-19 disease, currently raging across the world. The virus has now infected more than 43.89 million individuals and claimed over 1.16 million lives. The study titled, "Spike glycoprotein and host cell determinants of SARS-CoV-2 entry and cytopathic effects," is released on the preprint server bioRxiv* in October 2020.

27 Oct 2020

ACROBiosystems and the Fight Against COVID-19

In this interview, Dr. Yinang Jiang discusses ACROBiosystems and their efforts in the fight against COVID-19 and the search for a vaccine

From ACROBiosystems 23 Oct 2020

Researchers apply a novel technique to improve understanding of liver disease, immune activation

Human cells are encased by a membrane coated with diverse sugar molecules known as glycans. These glycans play many roles in health and disease, making them important to understand.

20 Oct 2020